Table 4.

Preferences for characteristics of HIV antiretroviral therapy: Results from a scale-adjusted latent class model (N=403)

				Preference classes
		Class 1	Class 2	Class 3	Class 4	Class 5
Class size		40.2%	24.3%	20.9%	10.2%	4.5%
Coefficient estimates
Dosing	1 pill once daily	1.391	1.094	1.343	3.784	−0.190
	2 pills once daily	−0.058	0.882	−0.390	−0.544	−0.050
	3 pills once daily	−0.862	−0.387	−1.549	−3.210	−0.258
	1 pill twice daily	−0.472	−1.590	0.595	−0.030	0.498
Administration	Meal requirement	−0.527	−2.631	1.047	0.490	−0.267
	Large pill	0.074	1.203	−1.905	0.007	−0.017
	Neither	0.453	1.428	0.858	−0.497	0.284
Side effect	None	3.046	4.655	3.191	2.909	0.091
	Moderate	−3.046	−4.655	−3.191	−2.909	−0.091
Long-term risk	Low	2.663	3.465	2.244	1.744	0.593
	High	−2.663	−3.465	−2.244	−1.744	−0.593
Intercept		1.057	0.559	0.317	−0.304	−1.630
Study cohort	Duke	−0.012	−0.203	0.341	0.208	−0.334
	South Carolina	−0.110	0.482	0.576	−0.079	−0.870
	Online panel	0.122	−0.280	−0.917	−0.129	1.203
Coefficient ranges
Dosing		2.25	2.68	2.89	6.99	0.76
Administration		0.98	4.06	2.95	0.99	0.55
Side effect		6.09	9.31	6.38	5.82	0.18
Long-term risk		5.33	6.93	4.49	3.49	1.19
Importance of attributes
Dosing		15%	12%	17%	40%	28%
Administration		7%	18%	18%	6%	21%
Side effect		42%	41%	38%	34%	7%
Long-term risk		36%	30%	27%	20%	44%

Notes to Table 4.

Respondents were asked to complete 16 choice tasks; each choice task was comprised of 3 treatment options. A total of 16 questions were skipped across the three cohorts.

The relative importance of attribute levels is described by coefficient estimates from a scale-adjusted latent class model with 5 preference classes and 3 continuous normally distributed scale factors.

The relative importance of attributes is described by the range of each attribute’s coefficient estimates as a share of the total range across attributes.